Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-19 is a small-molecule inhibitor targeting the PD-1/PD-L1 protein-protein interaction. With an IC50 of 62.3 nM, it effectively inhibits the binding of PD-1 to PD-L1, thereby modulating immune responses. This compound is suitable for research applications in cancer immunotherapy, as well as studies focused on infectious and autoimmune diseases. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-17 is a potent inhibitor of the PD-1/PD-L1 interaction, with an IC50 value of 26.8 nM. This compound serves as a valuable lead in the development of PD-1/PD-L1 inhibitors, making it an important tool for cancer research. Its ability to modulate immune checkpoint pathways highlights its potential in the exploration of cancer immunotherapy strategies. -
PD-1/PD-L1 Inhibitor
HBV/HDV-IN-1 is a potent inhibitor of PD-1/PD-L1 interactions, demonstrating EC50 values of 8 nM for T cell activation and 35 nM for PD-L1 internalization. This compound is essential for investigating the role of immune checkpoint modulation in hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. Its ability to enhance T cell responses makes it valuable for research in immunotherapy and viral pathogenesis. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-52 is an orally bioavailable inhibitor of the PD-1/PD-L1 interaction, demonstrating an IC50 of 109.9 nM. This compound exhibits significant antitumor effects, as evidenced by a tumor growth inhibition (TGI) of 49.6% in a C57BL/6 mouse xenograft model utilizing human PD-1-expressing MC38 colon cancer cells. Research applications include the exploration of immune checkpoint modulation and therapeutic strategies in cancer treatment. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-31 is a potent inhibitor of the PD-1/PD-L1 pathway, demonstrating an IC50 value of 2.2 nM. This compound enhances the secretion of interferon-gamma (IFN-γ) and stimulates the immune response of peripheral blood mononuclear cells (PBMCs), leading to the inhibition of tumor cell proliferation. PD-1/PD-L1-IN-31 is valuable for research applications focused on cancer immunotherapy and the modulation of immune checkpoints. -
PD-1/PD-L1 Inhibitor
PD-1-IN-25 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 value of 10.2 nM as determined by HTRF assay. This compound enhances CD8+ T cell activation by disrupting PD-1/PD-L1 signaling pathways. PD-1-IN-25 demonstrates significant potential for delaying tumor growth, making it a valuable tool for cancer immunotherapy research. -
PD-1/PD-L1 Inhibitor
BMS-242 is a small molecule inhibitor targeting the PD-1/PD-L1 interaction. It effectively binds to the hydrophobic channel pocket of PD-L1, disrupting the PD-1/PD-L1 immune checkpoint pathway. This action enhances anti-tumor immunity, making BMS-242 a valuable tool for cancer research and therapeutic studies focused on immune modulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-24 is a potent inhibitor of the PD-1/PD-L1 pathway, exhibiting an IC50 value of 1.57 nM. This compound effectively restores T-cell function by significantly increasing the levels of IFN-γ at the cellular level. With low toxicity towards peripheral blood mononuclear cells (PBMCs), PD-1/PD-L1-IN-24 is suitable for research applications focused on cancer immunotherapy and autoimmunity studies. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-21 is a small-molecule inhibitor targeting the PD-1/PD-L1 protein-protein interaction, exhibiting an IC50 of 4.99 μM. This compound effectively blocks PD-1 and PD-L1, making it a valuable tool for research into cancer, infectious diseases, and autoimmune conditions. Its ability to disrupt this immune checkpoint pathway positions PD-1/PD-L1-IN-21 as a significant reagent for studies aimed at enhancing anti-tumor immunity and understanding immune responses. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-53 is a potent inhibitor of the PD-1/PD-L1 and VISTA signaling pathways. This compound is primarily utilized in anti-cancer research to investigate immune checkpoint mechanisms and enhance T-cell activation. PD-1/PD-L1-IN-53 provides valuable insights for studies focused on tumor microenvironments and immunotherapy responses. -
PD-L1/VISTA Inhibitor
PD-L1/VISTA-IN-1 is a potent dual-target inhibitor of programmed death ligand 1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA). This compound effectively disrupts the PD-1/PD-L1 interaction with an IC50 of 0.1492 μM and inhibits the VISTA pathway with a KD of 0.2723 μM, promoting T cell reactivation. PD-L1/VISTA-IN-1 demonstrates significant anti-tumor activity, making it a valuable tool for cancer immunotherapy research. -
PD-1/PD-L1 Inhibitor
HBV/HDV-IN-2 is a potent inhibitor of both hepatitis B virus (HBV) and hepatitis D virus (HDV), as well as the PD-1/PD-L1 pathway. It exhibits an EC50 of 35 nM for T cell activation, making it a valuable tool for investigating immune modulation in viral infections. This compound is applicable in research aimed at understanding the interplay between viral infections and immune checkpoint regulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-55 is a potent inhibitor targeting the PD-1/PD-L1 immune checkpoint pathway, exhibiting an IC50 of 4.8 nM. This compound enhances the secretion of IFN-γ and decreases the incidence of late apoptosis in PD-L1 expressing cells. PD-1/PD-L1-IN-55 is valuable for research applications in cancer therapy and immunology, particularly in studies aimed at restoring T-cell activation and modulating immune responses. -
PD-1/PD-L1 Inhibitor
PD1-PDL1-IN 2 is a potent and selective inhibitor of the PD-1/PD-L1 pathway. This compound demonstrates significant antitumor activity in vivo by promoting cytotoxic T-cell infiltration into tumors and inducing interleukin-2 (IL-2) expression. Additionally, PD1-PDL1-IN 2 strongly inhibits the mRNA expression of TGF-β, making it a valuable tool for research in cancer immunotherapy and the modulation of immune responses. -
PD-L1 Inhibitor
PD-L1-IN-7 is a potent inhibitor of programmed cell death ligand 1 (PD-L1), effectively disrupting the PD-1/PD-L1 interaction with an IC50 of 0.2 nM. This compound facilitates the internalization and retention of PD-L1 within cells, alters glycosylation patterns, and promotes PD-L1 degradation. PD-L1-IN-7 enhances T cell infiltration and boosts T cell cytotoxic function, making it a valuable tool for developing immunotherapeutic strategies against tumors. -
PD-1/PD-L1 Inhibitor
Human PD-L1 Inhibitor III is a selective inhibitor targeting the PD-1/PD-L1 pathway, which plays a critical role in immune evasion by tumors. By blocking the interaction between programmed cell death protein 1 (PD-1) and its ligand PD-L1, this compound enhances T-cell activity, promoting anti-tumor immune responses. It is valuable for researchers investigating cancer immunotherapy and assessing therapeutic strategies aimed at modulating immune checkpoint pathways. -
PD-L1 Inhibitor
PD-L1-IN-4 is a selective inhibitor of PD-L1, demonstrating potent inhibition of the PD-1/PD-L1 interaction with an IC50 value of 1.3 nM. This compound also enhances the PD-L1 inhibitory effect on T cells, with an EC50 of 152.8 nM. PD-L1-IN-4 is suitable for studies in cancer research, particularly in the context of immunotherapy and tumor microenvironment modulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-27 is a potent inhibitor of the PD-1/PD-L1 pathway, demonstrating an IC50 value of 134 nM. This compound exhibits significant antitumor activity while maintaining low cytotoxicity towards T cells. Additionally, PD-1/PD-L1-IN-27 effectively activates CD8+ T cells and mitigates T cell exhaustion, making it a valuable tool for immuno-oncology research applications. -
PD-1/PD-L1 Inhibitor
SWS1 is a d-(+)-biotin-conjugated inhibitor of PD-L1 with an IC50 of 1.8 nM. It has demonstrated significant anticancer activity by enhancing tumor-infiltrating lymphocyte populations and inducing anti-tumor effects in the B16-F10 mouse model, achieving a tumor growth inhibition rate of 66.1%. SWS1 is suitable for research applications focused on immunotherapy and tumor microenvironment studies. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-34 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 0.029 μM, and demonstrates a binding affinity towards PD-L1 with a KD of 0.1554 μM. This compound activates the immune microenvironment, showcasing significant anti-tumor activity which reinforces its potential in cancer immunotherapy research. PD-1/PD-L1-IN-34 is an invaluable tool for elucidating mechanisms of immune modulation and evaluating therapeutic strategies in oncology. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-28 is a potent inhibitor of the PD-1/PD-L1 signaling pathway, exhibiting an IC50 value of 0.744 µM. This compound demonstrates significant potential in the modulation of tumor immunity, making it a valuable reagent for cancer immunotherapy research. Its ability to disrupt immune checkpoint interactions positions PD-1/PD-L1-IN-28 as an important tool for studying immune responses in various tumor models. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-4 is a potent dual-target inhibitor of CYP51 and PD-L1, demonstrating IC50 values of 0.17 μM and 0.021 μM, respectively. This compound exhibits significant antifungal activity and is effective against drug-resistant fungal strains in vitro. CYP51/PD-L1-IN-4 is suitable for research applications focused on fungal infections and the interplay between fungal pathogens and immune checkpoint regulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-22 is a small-molecule inhibitor specifically targeting the PD-1/PD-L1 protein-protein interaction. With an IC50 value of 0.732 μM, it effectively disrupts this pathway, making it a valuable tool in cancer, infectious disease, and autoimmune disease research. Its ability to modulate immune responses positions PD-1/PD-L1-IN-22 as a significant compound for therapeutic development in immunooncology and related fields. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-18 is a small-molecule inhibitor that specifically targets the PD-1/PD-L1 protein-protein interaction, demonstrating an IC50 of 1.054 μM. This compound effectively blocks PD-1/PD-L1 signaling, facilitating enhanced T-cell activation and antitumor responses. It is valuable for research applications focused on immunotherapy and cancer treatment strategies. -
PD-L1 Inhibitor
PD-L1-IN-8 is a selective PD-L1 inhibitor with an IC50 of 0.89 nM. It demonstrates low inhibition of cytochrome P450 enzymes and minimal hERG activity, indicating a favorable safety profile. This compound is specifically useful in the investigation of PD-L1 mediated immune evasion in colon cancer research, contributing to the understanding of tumor-immune system interactions. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-25 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 value of 16.17 nM. This compound effectively enhances T cell antitumor immunity in peripheral blood mononuclear cells (PBMCs). PD-1/PD-L1-IN-25 is instrumental for cancer research, particularly in studies focused on immunotherapy and tumor microenvironment modulation. -
PD-L1/CD-73 Inhibitor
PD-L1/CD-73-IN-1 is a potent inhibitor of PD-L1 and CD73, exhibiting IC50 values of 6 nM and 0.773 μM, respectively. This compound demonstrates significant biological activity by inhibiting tumor cell growth both in vitro and in vivo. It is an essential tool for research applications focused on immune modulation and cancer therapy. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-58 is a selective inhibitor of the PD-1/PD-L1 pathway, demonstrating a dissociation constant (KD) of 77.60 nM for PD-L1 in comparison to PD-1. This compound exhibits oral bioactivity and is particularly relevant for investigations into immune modulation and potential therapeutic strategies against influenza A virus. Its mechanism of action makes it a valuable tool for research aimed at understanding and manipulating immune responses in various disease contexts. -
PD-1/PD-L1 Inhibitor
LH1306 is a C2-symmetric inhibitor specifically targeting the PD-1/PD-L1 protein-protein interaction, demonstrating an IC50 value of 25 nM. This compound is pivotal for studies investigating immune checkpoint blockade and its potential applications in anti-tumor research. By modulating immune responses, LH1306 serves as a valuable tool for exploring therapeutic strategies in cancer immunotherapy. -
Inflammatory Cytokine Inhibitor
JTE-607 is a selective inhibitor targeting the Cleavage and Polyadenylation Specificity Factor 3 (CPSF3), demonstrating potent suppression of inflammatory cytokine synthesis. This compound effectively reduces the production of key inflammatory cytokines, including TNF-α, IL-1β, IL-6, IL-8, and IL-10 in LPS-stimulated human peripheral blood mononuclear cells (PBMCs) with IC50 values of 11, 5.9, 8.8, 7.3, and 9.1 nM, respectively. JTE-607 is utilized in research applications focused on understanding and mitigating inflammatory responses and endotoxin shock. -
IL-17A Inhibitor
LY3509754 is a potent IL-17A inhibitor, demonstrating IC50 values of less than 9.45 nM in alphaLISA assays and 9.3 nM in HT-29 cell assays. This compound's selective inhibition of IL-17A makes it a valuable tool for investigating the role of IL-17A in inflammatory diseases and immune responses. Its use in research applications can help elucidate the therapeutic potential for conditions associated with IL-17A signaling. -
IL6/STAT3 Inhibitor
Angoline is a selective inhibitor of the IL6/STAT3 signaling pathway, demonstrating an IC50 of 11.56 μM. It effectively inhibits the phosphorylation of STAT3, leading to reduced expression of target genes associated with cancer progression. This compound is valuable for research applications focused on cancer biology and the modulation of inflammatory responses. -
Cyclophilin Inhibitor
Rencofilstat (CRV431) is a potent pan-cyclophilin inhibitor that targets multiple cyclophilins with IC50 values of 2.5 nM for Cyp A, 3.1 nM for Cyp B, 2.8 nM for Cyp D, and 7.3 nM for Cyp G. This compound is effective in reducing fibrosis and tumor growth in chronic liver disease models. Rencofilstat is suitable for research applications related to nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma, and liver diseases induced by viral hepatitis. -
Nrf2 inhibitory protein Keap-1 Activator
KMS99220 is a potent activator of the Nrf2 inhibitory protein Keap-1, capable of crossing the blood-brain barrier. This compound enhances AMPK activity and activates the Nrf2 signaling pathway, leading to decreased phosphorylation of IκB, reduced translocation of NFκB, and modulation of MAPK pathways. KMS99220 promotes the expression of neuroprotective genes, including HO-1 and NQO1, and exhibits anti-inflammatory properties by inhibiting iNOS and IL-1β production. Its application in research focuses on understanding neurodegenerative diseases like Parkinson's disease, particularly its effects on dopaminergic neuron preservation and associated motor dysfunction. -
IL-2/IL-2Rα Inhibitor
SP4206 is an inhibitor of the IL-2/IL-2Rα interaction, exhibiting high-affinity binding to IL-2 with a dissociation constant (Kd) of 70 nM. By effectively blocking the interaction with its natural receptor IL-2Rα, which has a Kd of 10 nM, SP4206 has significant potential for modulating immune responses. This compound is valuable for research applications focused on autoimmune diseases, cancer immunotherapy, and enhancing our understanding of IL-2-mediated signaling pathways. -
IL-18 Inhibitor
NSC80734 is an IL-18 inhibitor that effectively disrupts the binding of human IL-18 to ectromelia virus IL-18 binding protein (IL-18BP). This compound inhibits the IL-18-mediated production of interferon-gamma (IFN-γ), making it a valuable tool for studying the role of IL-18 in inflammatory processes and immune responses. NSC80734 is applicable in research focusing on cytokine signaling and related biological pathways. -
IL-17C/IL-17RE Interaction Inhibitor
Lib2-1 is a macrocyclic peptide that functions as an inhibitor of the IL-17C/IL-17RE interaction. This compound demonstrates significant potential in modulating inflammatory responses, making it a valuable tool in the study of autoimmune and inflammatory diseases. Researchers can utilize Lib2-1 to investigate the underlying mechanisms of IL-17C signaling and its implications in various pathological conditions. -
TYK2 Inhibitor
QL-1200186 is a selective, orally active allosteric inhibitor specifically targeting the pseudokinase domain JH2 of tyrosine kinase TYK2, exhibiting an IC50 of 0.06 nM with 164-fold selectivity over TYK1 JH2 (IC50 = 9.85 nM). By stabilizing the TYK2 JH2 conformation, QL-1200186 inhibits the activity of the JH1 catalytic domain and disrupts the IFNα, IL-12/IL-23-mediated JAK-STAT signaling pathway. This compound effectively reduces the production of Th1/Th17-related cytokines and has shown promise in alleviating skin inflammation in Imiquimod-induced psoriasis models, making it relevant for the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE). -
IL-18 Inhibitor
NSC61610 is an inhibitor of interleukin-18 (IL-18) that disrupts the binding of human IL-18 to the ectromelia virus IL-18 binding protein (IL-18BP). It effectively inhibits the formation of the hIL-18:ectvIL-18BP complex, demonstrating an IC50 of approximately 6 µM. This compound is valuable for research applications involving inflammatory responses and the study of viral interactions with host immune mechanisms. -
IL-1 Inhibitor
Lys-D-Pro-Thr is an IL-1β analogue, specifically targeting the positions 193-195 of the IL-1β protein. It acts as a potent inhibitor of IL-1, playing a critical role in regulating inflammatory responses. This reagent is valuable for research applications focused on inflammatory pathways, autoimmune diseases, and the modulation of cytokine signaling. -
IL-17A Inhibitor
Navepdekinra is a potent inhibitor of interleukin-17A (IL-17A), with an IC50 of 10.81 nM. By disrupting the interaction between IL-17A and its receptor, Navepdekinra effectively suppresses downstream pro-inflammatory signaling pathways. This compound has demonstrated efficacy in reducing arthritis symptoms in a collagen-induced arthritis rat model and is applicable to research in psoriasis, psoriatic arthritis, and ankylosing spondylitis. -
CD47-SIRPα Signalling Inhibitor
RS17 is a CD47-SIRPα signaling inhibitor that disrupts the interaction between CD47 and its ligand, SIRPα, on macrophage surfaces. By binding to CD47, RS17 prevents the transmission of signals that enable selective phagocytosis, thereby promoting the recognition and clearance of tumor cells by macrophages. This peptide is valuable for researching anti-tumor responses and mechanisms of immune evasion in cancer. -
SIK Inhibitor
PF-07899895 is a selective SIK inhibitor, demonstrating potent activity with IC50 values of 1.2 nM, 0.9 nM, and 1.8 nM against SIK1, SIK2, and SIK3, respectively. This compound effectively modulates the production of the anti-inflammatory cytokine IL-10 in immune cells. PF-07899895 is highly relevant for research into inflammatory diseases and understanding immunological responses. -
IL-23R Inhibitor
IL-23R inhibitor peptide-1 is a potent interleukin-23 receptor inhibitor with an IC50 of 0.0069 μM. It is designed to modulate the signaling pathway of IL-23, which plays a critical role in the pathogenesis of various autoimmune diseases. This reagent is suitable for research applications focused on inflammatory responses and therapeutic strategies targeting IL-23 signaling. -
IL-2 Inhibitor
IL-2-IN-1 is a potent inhibitor of interleukin-2 (IL-2), exhibiting an IC50 value of 1978 nM. It demonstrates significant antiproliferative activity, making it a valuable tool for research in immune modulation and cytokine signaling. This compound is ideal for studies focused on T cell regulation and potential therapeutic applications in autoimmune diseases and cancers linked to IL-2 signaling. -
STING Inhibitor
STING-IN-11 is a potent STING inhibitor with an IC50 of 37.8 nM. By blocking the palmitoylation of the STING protein, it effectively inhibits STING-mediated downstream signaling and associated inflammatory pathways. This compound demonstrates favorable in vivo safety, making it an excellent candidate for research into STING-related inflammatory and autoimmune diseases. -
IL-20/PRINS Inhibitor
Abacavir hydroxyacetate is an orally active inhibitor of IL-20 and PRINS. This compound demonstrates significant immune modulation, effectively reducing the proliferation rate of skin cells in psoriasis. It serves as a valuable tool for investigating inflammatory skin disorders and potential therapeutic strategies in related research applications. -
IL-1β Inhibitor
IL-1β-IN-2 is a potent inhibitor of interleukin-1 beta (IL-1β), a key mediator in inflammatory processes. This cannabigerol derivative exhibits significant anti-inflammatory and analgesic effects, making it a valuable tool for research into conditions driven by IL-1β signaling. IL-1β-IN-2 is suitable for studies focused on inflammatory diseases and pain management, aiding in the understanding and development of therapeutic strategies targeting IL-1β. -
IL-1β Inhibitor
IL-1β-IN-1 is a selective inhibitor of interleukin-1 beta (IL-1β), a key cytokine involved in inflammatory processes. This compound demonstrates significant anti-inflammatory and analgesic effects, making it a valuable tool in research focused on chronic inflammatory conditions and pain management. Its potency and specificity for IL-1β allow for detailed studies on its biological roles and therapeutic applications. -
IL-17 Inhibitor
IL-17-IN-2 is a potent inhibitor of interleukin-17 (IL-17) with an IC50 of less than 0.4 μM, as demonstrated in both HTRF and NHK assays. This compound effectively disrupts IL-17 signaling, making it valuable for research related to inflammatory diseases and immune response modulation. Its significant biological activity allows for exploration in therapeutic contexts targeting IL-17-mediated pathways.
